Obiettivo Antibiotics resistance of pathogens is a major threat to public health and safety. The rapid spread of resistant strains increases the risk of epidemics. This issue also includes preparedness to deal with bio-terrorism. The objectives of the ET-PA project are to develop an open, generic platform to enable the development of new classes of protein-antibiotics. The key technology (REPPs) is based on a principle that is proprietary to one of the participating SMEs, consisting of rationally modified class II restriction enzymes (RE) fused to cell penetration peptide sequences (PP) that selectively allow microbial cell penetration. Introduction of a REPP system into pathogens would lead to effective cell killing. The REPP will be designed to inactivate major microbial pathogens, i.e. S. aureus, P. aeruginosa and C. Albicans. Addressing these ambitious objectives will require a Co-operative Research setup with complementing expertise and resources, coming both from high-tech SMEs and expert academic RTD partners. The ET-PA project will be divided into four work packages:1.Discovery -The design of a technology platform for the discovery of PP sequences for proper function in antibiotic REPP constructs.2.Characterization -extensive characterization of the biological activity of antibiotic REPP constructs.3.Technological platform - configuration of a semi-automatic and embedding technology platform that enables a coherent and unified approach for a rapid translation of REPP components into protein antibiotics.4.Management - to assure, consolidation and coordination of the ET-PA project, support and protection of Intellectual Property, and contacts to subsequently license the outcomes to a third-party end-user.The commitment and collective efforts of all participants is the best warranty for a success of the ET-PA project that will provide a technology platform to translate the most effective horizontal bacterial defence system into innovative medicine. Campo scientifico medical and health scienceshealth sciencespublic healthnatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsproteomicsmedical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsantibioticsmedical and health sciencesbasic medicinepharmacology and pharmacydrug resistanceantibiotic resistancenatural sciencesbiological sciencesbiochemistrybiomoleculesproteinsenzymes Programma(i) FP6-SME - Horizontal research activities involving SMEs: Specific activities covering wider field of research under the Focusing and Integrating Community Research programme 2002-2006. Argomento(i) SME-1 - Co-operative Research (all areas of science and technology) Invito a presentare proposte FP6-2003-SME-1 Vedi altri progetti per questo bando Meccanismo di finanziamento Data not available Coordinatore ADRIACELL SRL. Contributo UE Nessun dato Indirizzo S.S.14km163.5 TRIESTE Italia Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato Partecipanti (4) Classifica in ordine alfabetico Classifica per Contributo UE Espandi tutto Riduci tutto BIA SEPARATIONS D.O.O. Slovenia Contributo UE Nessun dato Indirizzo Teslova 30 LJUBLJANA Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato HECUS X-RAY SYSTEMS GMBH Austria Contributo UE Nessun dato Indirizzo Moserhofgasse 15 GRAZ Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAET BONN Germania Contributo UE Nessun dato Indirizzo Sigmund-Freud-Strasse 25 BONN Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato UNIVERSITA DEGLI STUDI DI TRIESTE. Italia Contributo UE Nessun dato Indirizzo Piazzale Europa 1 TRIESTE Mostra sulla mappa Collegamenti Sito web Opens in new window Costo totale Nessun dato
